{"id":54583,"date":"2023-03-07T15:06:19","date_gmt":"2023-03-07T14:06:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/"},"modified":"2023-03-07T15:06:19","modified_gmt":"2023-03-07T14:06:19","slug":"paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/","title":{"rendered":"Paragonix Technologies Raises $24M in Series B Led by Signet Healthcare Partners"},"content":{"rendered":"
\n

\nLeader in organ transplant technologies secures institutional growth capital to drive organ preservation innovation and commercial expansion <\/i>\n<\/p>\n

<\/a><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc<\/a>., a leading organ transplant company, today announced that it has secured $24 million in Series B funding, led by Signet Healthcare Partners<\/a>. This growth investment will bolster Paragonix Technologies\u2019 commercial footprint, including its ongoing extension of clinical service offerings and inventory expansion, and will enable the Company to further advance transplant innovations.\n<\/p>\n

\nParagonix Technologies, a leading developer and manufacturer in the organ transplant industry, offers three FDA-cleared and CE-marked devices: Paragonix SherpaPak\u00ae<\/sup>, LUNGguard\u2122<\/sup> Donor Lung Preservation System, and the LIVERguard\u2122<\/sup> System. All three devices utilize first-of-its-kind preservation methods that present a significant improvement over traditional ice and cooler practices still used today. Paragonix devices combine clinically-proven, stable preservation technology with a comprehensive clinical support network, augmented by the largest clinical registries of organ preservation data worldwide. They also incorporate digital tracking and communication technologies to provide complete control over organ tracking, monitoring, and reporting.\n<\/p>\n

\n\u201cThe future of Paragonix is full of promise and excitement. Our focus remains on creating the best possible product to help more people receive a second chance at life in a safe and effective manner,\u201d said Dr. Lisa Anderson, CEO of Paragonix Technologies. \u201cThis growth investment arrives at a critical moment as we strive to meet rising demands for our organ preservation products. We are excited to rapidly advance our innovation pipeline to enhance our ability to safely preserve and transport as many donor organs as possible. We are thrilled to have Signet as our partner in accelerating growth and achieving our ambitious long-term strategic objectives, and we look forward to leveraging their vast experience in the medical device market.\u201d\n<\/p>\n

\nAshley Friedman, Managing Director at Signet Healthcare Partners, stated, “At Signet, we seek to invest in highly innovative and fast-growing healthcare companies. Paragonix has rapidly become a leader in the organ transplant market and is having a significant impact on the future of transplant medicine. We are impressed by their commercial and clinical achievements to date and are excited to partner with their dedicated and versatile team during the next phase of growth.”\n<\/p>\n

\nIn 2022, over 1 in 5 thoracic donor organs transplanted in the U.S. were preserved and transported using a Paragonix device. The Paragonix SherpaPak\u00ae<\/sup> System is the most commonly utilized FDA-cleared and CE-marked medical device for U.S. heart preservation and transport. According to 2022 transplant data, 19 out of the 30 largest U.S. heart transplant programs, as well as over 80 global transplant programs, rely on Paragonix devices to safely preserve, track, and transport critical donor organs to their intended recipients.\n<\/p>\n

\nGunderson Dettmer acted as legal counsel for Paragonix Technologies. Sheppard, Mullin, Richter & Hampton LLP and Knobbe Martens acted as legal counsel for Signet Healthcare Partners. Terms of the transaction were not disclosed.\n<\/p>\n

\nAbout Paragonix Technologies<\/b>\n<\/p>\n

\nParagonix Technologies (\u201cParagonix\u201d) is a leading provider of Advanced Organ Preservation (\u201cAOP\u201d) devices that safeguard donor organs during the journey between donor and recipient patients. Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ in transit. Every Paragonix AOP device natively integrates with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit www.paragonixtechnologies.com<\/a>\n<\/p>\n

\nAbout Signet Healthcare Partners<\/b>\n<\/p>\n

\nSignet Healthcare Partners (“Signet”) is a leading provider of growth capital to innovative healthcare companies, specializing in pharmaceutical and medical device sectors. The firm maintains a disciplined, yet flexible investment approach and collaborates closely with its portfolio companies to enhance value. With a proven track record of successful investments over its 25-year history, Signet has raised cumulative capital commitments exceeding $500 million and invested in over 55 companies. For more information, visit www.signethealthcarepartners.com<\/a>\n<\/p>\n

\nFollow us on Twitter: @ParagonixSherpa<\/a>
Connect with us on LinkedIn: Paragonix Technologies<\/a>
Like Us on Facebook: Paragonix SherpaPak<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia: <\/b>Adam Lafreniere, Sr. Director, Marketing
\n
marketing@paragonixtechnologies.com<\/a><\/span>
L-420, Rev 0\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Leader in organ transplant technologies secures institutional growth capital to drive organ preservation innovation and commercial expansion CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc., a leading organ transplant company, today announced that it has secured $24 million in Series B funding, led by Signet Healthcare Partners. This growth investment will bolster Paragonix Technologies\u2019 commercial footprint, including its … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54583","6":"format-standard","7":"category-industry"},"yoast_head":"\nParagonix Technologies Raises $24M in Series B Led by Signet Healthcare Partners - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Paragonix Technologies Raises $24M in Series B Led by Signet Healthcare Partners - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Leader in organ transplant technologies secures institutional growth capital to drive organ preservation innovation and commercial expansion CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc., a leading organ transplant company, today announced that it has secured $24 million in Series B funding, led by Signet Healthcare Partners. This growth investment will bolster Paragonix Technologies\u2019 commercial footprint, including its ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-07T14:06:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230307005343\/en\/1194317\/21\/Blue_Logo_with_Tagline.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Paragonix Technologies Raises $24M in Series B Led by Signet Healthcare Partners\",\"datePublished\":\"2023-03-07T14:06:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\\\/\"},\"wordCount\":679,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230307005343\\\/en\\\/1194317\\\/21\\\/Blue_Logo_with_Tagline.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\\\/\",\"name\":\"Paragonix Technologies Raises $24M in Series B Led by Signet Healthcare Partners - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230307005343\\\/en\\\/1194317\\\/21\\\/Blue_Logo_with_Tagline.jpg\",\"datePublished\":\"2023-03-07T14:06:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230307005343\\\/en\\\/1194317\\\/21\\\/Blue_Logo_with_Tagline.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230307005343\\\/en\\\/1194317\\\/21\\\/Blue_Logo_with_Tagline.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Paragonix Technologies Raises $24M in Series B Led by Signet Healthcare Partners\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Paragonix Technologies Raises $24M in Series B Led by Signet Healthcare Partners - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/","og_locale":"en_US","og_type":"article","og_title":"Paragonix Technologies Raises $24M in Series B Led by Signet Healthcare Partners - Pharma Trend","og_description":"Leader in organ transplant technologies secures institutional growth capital to drive organ preservation innovation and commercial expansion CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc., a leading organ transplant company, today announced that it has secured $24 million in Series B funding, led by Signet Healthcare Partners. This growth investment will bolster Paragonix Technologies\u2019 commercial footprint, including its ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-07T14:06:19+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230307005343\/en\/1194317\/21\/Blue_Logo_with_Tagline.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Paragonix Technologies Raises $24M in Series B Led by Signet Healthcare Partners","datePublished":"2023-03-07T14:06:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/"},"wordCount":679,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230307005343\/en\/1194317\/21\/Blue_Logo_with_Tagline.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/","url":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/","name":"Paragonix Technologies Raises $24M in Series B Led by Signet Healthcare Partners - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230307005343\/en\/1194317\/21\/Blue_Logo_with_Tagline.jpg","datePublished":"2023-03-07T14:06:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230307005343\/en\/1194317\/21\/Blue_Logo_with_Tagline.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230307005343\/en\/1194317\/21\/Blue_Logo_with_Tagline.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-raises-24m-in-series-b-led-by-signet-healthcare-partners\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Paragonix Technologies Raises $24M in Series B Led by Signet Healthcare Partners"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54583"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54583\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54583"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54583"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}